DEFI Gestion

DEFI Gestion SA is a private equity and venture capital firm based in Lausanne, Switzerland, managing nearly CHF 200 million in assets for both institutional and individual clients. The firm operates with two distinct teams: one focused on buy-outs and the other on venture capital investments. Approximately two-thirds of its funds are allocated to buy-outs, while one-third is directed towards venture capital opportunities. DEFI Gestion invests in a diverse range of sectors, including consumer goods, industrial, food, electronics, transport, medical and social services, leisure, logistics and distribution, automobiles, and health. In addition to its investment activities, the firm also provides advisory services for private equity funds.

Claude Suard

Partner and CFO

4 past transactions

NanoPowers

Series A in 2010
NanoPowers S.A. is a medical device company, founded in June 2004 that applies their unique and proprietary artificial muscle technology to restore or improve muscle function in humans.

Endosense

Series B in 2009
Endosense is a medical technology company dedicated to enhancing the efficacy, safety, and consistency of catheter ablation procedures used to treat cardiac arrhythmias. The company developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time and objective measure of contact force during ablation. The TactiCath received the CE mark in May 2009 and has undergone extensive pre-clinical and clinical testing, establishing a strong evidence base for the feasibility and safety of contact force sensing in catheter ablation. Endosense's innovations aim to improve patient outcomes and streamline ablation procedures in the field of cardiology.

Kuros Biosciences

Post in 2005
Kuros Biosciences is a Swiss biopharmaceutical company founded in 2000 as a spin‑off of ETH Zürich. It develops tissue‑repair and bone‑regeneration products built on proprietary technology platforms derived from research at ETH Zürich, the University of Zürich and CalTech. The company acquired Xpand Biotechnology in 2017 to expand its MagnetOs family of bone graft substitutes, which are approved in the EU for orthopedic, spinal and dental applications and in the United States for posterolateral spinal fusion. A putty formulation is pending regulatory submission. Neuroseal, a novel dural‑sealing biomaterial, is under CE review. Kuros also pursues a pipeline of clinical‑stage products, including KUR‑111 and KUR‑113 for fracture repair and a fibrin‑PTH combination that promotes bone formation. The company collaborates with Checkmate Pharmaceuticals on the oncology candidate CYT003 and maintains a legacy portfolio of medical‑device and pharmaceutical assets.

Kuros Biosciences

Post in 2005
Kuros Biosciences is a Swiss biopharmaceutical company founded in 2000 as a spin‑off of ETH Zürich. It develops tissue‑repair and bone‑regeneration products built on proprietary technology platforms derived from research at ETH Zürich, the University of Zürich and CalTech. The company acquired Xpand Biotechnology in 2017 to expand its MagnetOs family of bone graft substitutes, which are approved in the EU for orthopedic, spinal and dental applications and in the United States for posterolateral spinal fusion. A putty formulation is pending regulatory submission. Neuroseal, a novel dural‑sealing biomaterial, is under CE review. Kuros also pursues a pipeline of clinical‑stage products, including KUR‑111 and KUR‑113 for fracture repair and a fibrin‑PTH combination that promotes bone formation. The company collaborates with Checkmate Pharmaceuticals on the oncology candidate CYT003 and maintains a legacy portfolio of medical‑device and pharmaceutical assets.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.